Form 8-K - Current report:
SEC Accession No. 0001839882-24-029804
Filing Date
2024-09-19
Accepted
2024-09-19 07:05:26
Documents
14
Period of Report
2024-09-19
Items
Item 7.01: Regulation FD Disclosure
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 CURRENT REPORT tnxp-8k_091824.htm   iXBRL 8-K 30159
2 PRESS RELEASE OF THE COMPANY, SEPTEMBER 18, 2024 ex99-01.htm EX-99.01 25551
  Complete submission text file 0001839882-24-029804.txt   237719

Data Files

Seq Description Document Type Size
3 XBRL SCHEMA FILE tnxp-20240918.xsd EX-101.SCH 3024
4 XBRL LABEL FILE tnxp-20240918_lab.xml EX-101.LAB 34240
5 XBRL PRESENTATION FILE tnxp-20240918_pre.xml EX-101.PRE 22365
16 EXTRACTED XBRL INSTANCE DOCUMENT tnxp-8k_091824_htm.xml XML 3543
Mailing Address 26 MAIN STREET, SUITE 101 CHATHAM NJ 07928
Business Address 26 MAIN STREET, SUITE 101 CHATHAM NJ 07928 212-980-9155
Tonix Pharmaceuticals Holding Corp. (Filer) CIK: 0001430306 (see all company filings)

EIN.: 261434750 | State of Incorp.: NV | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-36019 | Film No.: 241309075
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)